RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Editorial

Keywords: geriatric oncology, International Society of Geriatric Oncology, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Elderly patients deserve better

Elderly patients
deserve better

Two sets of statistics have recently been published which together have major implications for Europe’s cancer patients of the future. In February the International Agency for Research on Cancer revealed that the number of new cases in Europe rose by 10% between 2004 and 2006, from 2.9 million to 3.2 million. In March, a report published in the Annals of Oncology estimated that the rate of cancer mortality in Europe fell by 12.5% between 1987 and 2002, from 191 to 167 per 100,000 head of population

» Kathy Redmond

To read the complete article please click on the pdf icon

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.